Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 active)
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (8)
Type
(
1 selected
)
Type
Guidance (283)
Guidance programme
(
2 selected
)
Guidance programme
Diagnostics guidance (2)
Health technology evaluations (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (15)
Medical technologies guidance (7)
Technology appraisal guidance (282)
Apply filters
Showing 76 to 100 of 283
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance programme: Highly specialised technologies guidance
Remove Guidance programme: Highly specialised technologies guidance filter
Guidance and quality standards awaiting development
Title
Type
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable TS ID 11989
Technology appraisal guidance
Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer (Review of TA662) [ID6404]
Technology appraisal guidance
Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]
Technology appraisal guidance
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]
Technology appraisal guidance
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]
Technology appraisal guidance
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID 5097]
Technology appraisal guidance
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]
Technology appraisal guidance
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]
Technology appraisal guidance
Edaravone for treating amyotrophic lateral sclerosis TS ID 11869
Technology appraisal guidance
Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide TS ID 10046
Technology appraisal guidance
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over TS ID 11847
Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms associated with menopause TS ID 11917
Technology appraisal guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer TS ID 10718
Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]
Technology appraisal guidance
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6338]
Technology appraisal guidance
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy TSID 12015
Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 ID4037
Technology appraisal guidance
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]
Technology appraisal guidance
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806
Technology appraisal guidance
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920
Technology appraisal guidance
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]
Technology appraisal guidance
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment TS ID 11963
Technology appraisal guidance
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]
Technology appraisal guidance
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]
Technology appraisal guidance
Galcanezumab for migraine TS ID 10663
Technology appraisal guidance
Previous page
1
2
3
Current page
4
5
6
…
12
Page
4
of
12
Next page
Results per page
10
25
50
All
Back to top